MedPath

Danazol

Generic Name
Danazol
Brand Names
Cyclomen
Drug Type
Small Molecule
Chemical Formula
C22H27NO2
CAS Number
17230-88-5
Unique Ingredient Identifier
N29QWW3BUO

Overview

A synthetic steroid with antigonadotropic and anti-estrogenic activities that acts as an anterior pituitary suppressant by inhibiting the pituitary output of gonadotropins. It possesses some androgenic properties. Danazol has been used in the treatment of endometriosis and some benign breast disorders.

Background

A synthetic steroid with antigonadotropic and anti-estrogenic activities that acts as an anterior pituitary suppressant by inhibiting the pituitary output of gonadotropins. It possesses some androgenic properties. Danazol has been used in the treatment of endometriosis and some benign breast disorders.

Indication

For the treatment of endometriosis and fibrocystic breast disease (in patients unresponsive to simple measures). Also used for the prophylactic treatment of all types of hereditary angioedema in males and females.

Associated Conditions

  • Endometriosis
  • Fibrocystic Disease of Breast
  • Hereditary Angioedema (HAE)
  • Refractory immune thrombocytopenia

FDA Approved Products

Danazol
Manufacturer:Teva Pharmaceuticals USA, Inc.
Route:ORAL
Strength:50 mg in 1 1
Approved: 2022/11/18
NDC:0555-0633
Danazol
Manufacturer:Lannett Company, Inc.
Route:ORAL
Strength:50 mg in 1 1
Approved: 2020/04/30
NDC:0527-1392
Danazol
Manufacturer:Chartwell RX, LLC.
Route:ORAL
Strength:50 mg in 1 1
Approved: 2023/06/22
NDC:62135-475
Danazol
Manufacturer:Chartwell RX, LLC.
Route:ORAL
Strength:200 mg in 1 1
Approved: 2023/06/22
NDC:62135-477
Danazol
Manufacturer:Chartwell RX, LLC.
Route:ORAL
Strength:100 mg in 1 1
Approved: 2023/06/22
NDC:62135-476

Singapore Approved Products

NAZOL CAPSULE 200 mg
Manufacturer:DUOPHARMA (M) SDN BHD
Form:CAPSULE
Strength:200 mg
Online:Yes
Approved: 1990/03/01
Approval:SIN03932P

Drug Development Updates

Stay informed with timely notifications on clinical trials and research advancements.

© Copyright 2025. All Rights Reserved by MedPath